178 related articles for article (PubMed ID: 27517639)
1. Combining chemotherapy and immune checkpoint blockade.
Collazo-Lorduy A; Galsky MD
Curr Opin Urol; 2016 Nov; 26(6):508-13. PubMed ID: 27517639
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
4. The landscape of immunotherapy in metastatic urothelial carcinoma.
Teo MY; Iyer G
Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
[TBL] [Abstract][Full Text] [Related]
5. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic properties of chemotherapy.
Fournier C; Rivera Vargas T; Martin T; Melis A; Apetoh L
Curr Opin Pharmacol; 2017 Aug; 35():83-88. PubMed ID: 28551360
[TBL] [Abstract][Full Text] [Related]
7. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
9. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
10. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.
Sanchez K; Page D; McArthur HL
Curr Probl Cancer; 2016; 40(2-4):151-162. PubMed ID: 27855963
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
13. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.
Shahabi V; Postow MA; Tuck D; Wolchok JD
Am J Clin Oncol; 2015 Feb; 38(1):90-7. PubMed ID: 25616204
[TBL] [Abstract][Full Text] [Related]
14. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
15. Current Role of Checkpoint Inhibitors in Urologic Cancers.
Attalla K; Sfakianos JP; Galsky MD
Cancer Treat Res; 2018; 175():241-258. PubMed ID: 30168125
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and immunotherapy: mapping the road ahead.
Cook AM; Lesterhuis WJ; Nowak AK; Lake RA
Curr Opin Immunol; 2016 Apr; 39():23-9. PubMed ID: 26724433
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
[TBL] [Abstract][Full Text] [Related]
20. The interplay of immunotherapy and chemotherapy: harnessing potential synergies.
Emens LA; Middleton G
Cancer Immunol Res; 2015 May; 3(5):436-43. PubMed ID: 25941355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
